Enhertu, a cancer drug by AstraZeneca, was the top-selling new drug in 2024 with sales of nearly Rs 58 crore. Over 3,100 new brands were launched, generating sales of Rs 1,097 crore. The cardiac, anti ...

With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth ...

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Rajeev highlighted how people from different parts of India had different preferences. Asked which is the highest-selling flavour and the lowest-selling flavour, he said 'chocolate and strawberry ...

IGC Pharma (IGC) announced the launch of Holiby, a wellness brand offering scientifically ... Try Now>> See the top stocks recommended by analysts >> Read More on IGC: India Globalization Capital ...